FOLD AMICUS THERAPEUTICS INC revenue, earnings and financials

For the quarter ended December 31, 2025, AMICUS THERAPEUTICS INC reported revenue of $185M (up 23.7% from a year earlier), net income of $1.69M and diluted EPS of $0.00; over the last four quarters revenue was $634M and net income −$27.1M; for the fiscal year ended December 2025 revenue was $634M, up 20.0% on the year before.

FOLD annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $634M, gross profit $561M, operating income $32.8M, net income −$27.1M (margin -4.3%), EPS −$0.09
• Fiscal year ended Dec 2024: revenue $528M, gross profit $475M, operating income $24.9M, net income −$56.1M (margin -10.6%), EPS −$0.18
• Fiscal year ended Dec 2023: revenue $399M, gross profit $362M, operating income −$77.2M, net income −$152M (margin -38.0%), EPS −$0.51
• Fiscal year ended Dec 2022: revenue $329M, gross profit $291M, operating income −$212M, net income −$237M (margin -71.9%), EPS −$0.82
• Fiscal year ended Dec 2021: revenue $306M, gross profit $271M, operating income −$206M, net income −$250M (margin -82.0%), EPS −$0.92

FOLD quarterly revenue and earnings

• Quarter ended Dec 31, 2025 (from the annual report): revenue $185M (up 23.7% year over year), net income $1.69M, EPS $0.00
• Quarter ended Sep 30, 2025: revenue $169M (up 19.5% year over year), net income $17.3M, EPS $0.06
• Quarter ended Jun 30, 2025: revenue $155M (up 22.1% year over year), net income −$24.4M, EPS −$0.08
• Quarter ended Mar 31, 2025: revenue $125M (up 13.4% year over year), net income −$21.7M, EPS −$0.07
• Quarter ended Dec 31, 2024 (from the annual report): revenue $150M (up 30.1% year over year), net income $14.7M, EPS $0.05
• Quarter ended Sep 30, 2024: revenue $142M (up 36.7% year over year), net income −$6.73M, EPS −$0.02
• Quarter ended Jun 30, 2024: revenue $127M (up 34.0% year over year), net income −$15.7M, EPS −$0.05
• Quarter ended Mar 31, 2024: revenue $110M (up 28.0% year over year), net income −$48.4M, EPS −$0.16
• Quarter ended Dec 31, 2023 (from the annual report): revenue $115M (up 30.6% year over year), net income −$33.8M, EPS −$0.11
• Quarter ended Sep 30, 2023: revenue $104M (up 26.7% year over year), net income −$21.6M, EPS −$0.07
• Quarter ended Jun 30, 2023: revenue $94.5M (up 17.1% year over year), net income −$43.2M, EPS −$0.15
• Quarter ended Mar 31, 2023: revenue $86.3M (up 9.6% year over year), net income −$52.9M, EPS −$0.18
• Quarter ended Dec 31, 2022 (from the annual report): revenue $88.1M (up 7.2% year over year), net income −$55.9M, EPS −$0.19
• Quarter ended Sep 30, 2022: revenue $81.7M (up 2.7% year over year), net income −$33.3M, EPS −$0.12
• Quarter ended Jun 30, 2022: revenue $80.7M (up 4.3% year over year), net income −$62.2M, EPS −$0.21
• Quarter ended Mar 31, 2022: revenue $78.7M (up 18.5% year over year), net income −$85.3M, EPS −$0.30
• Quarter ended Dec 31, 2021 (from the annual report): revenue $82.2M, net income −$83.3M, EPS −$0.29
• Quarter ended Sep 30, 2021: revenue $79.5M, net income −$50.3M, EPS −$0.19
• Quarter ended Jun 30, 2021: revenue $77.4M, net income −$51.2M, EPS −$0.19
• Quarter ended Mar 31, 2021: revenue $66.4M, net income −$65.7M, EPS −$0.25

FOLD cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $33.1M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$33.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$69.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$167M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$202M, share buybacks n/a

FOLD balance sheet

• Dec 31, 2025: cash $214M, total assets $950M, total liabilities $676M, shareholders' equity $274M
• Sep 30, 2025: cash $191M, total assets $869M, total liabilities $638M, shareholders' equity $230M
• Jun 30, 2025: cash $159M, total assets $815M, total liabilities $611M, shareholders' equity $204M
• Mar 31, 2025: cash $182M, total assets $790M, total liabilities $596M, shareholders' equity $194M
• Dec 31, 2024: cash $214M, total assets $785M, total liabilities $591M, shareholders' equity $194M
• Sep 30, 2024: cash $234M, total assets $787M, total liabilities $608M, shareholders' equity $179M
• Jun 30, 2024: cash $209M, total assets $749M, total liabilities $617M, shareholders' equity $133M
• Mar 31, 2024: cash $210M, total assets $722M, total liabilities $591M, shareholders' equity $131M

What is FOLD's revenue?

AMICUS THERAPEUTICS INC reported $634M of revenue over its last four quarters, through December 31, 2025.

Is FOLD profitable?

No. AMICUS THERAPEUTICS INC lost $27.1M over the last four quarters.

What is FOLD's EPS?

Diluted earnings per share over the last four quarters were −$0.09; $0.00 in the latest quarter.

FOLD ownership and insider trades · All stocks